GSK’s Jemperli In Search Of Lung Cancer Foothold And TIM-3 Combo Could Be Best Chance

Keytruda Head-To-Head Is Ambitious

The company wants to break into non-small cell lung cancer therapy but is unlikely to score a true hit in its head-to-head with Merck & Co’s blockbuster Keytruda.

GSK is rebuilding its presence in oncology, and hopes Jemperli can be the backbone of its immunotherapy franchise. • Source: GSK

GSK is trying to make up years of lost time in oncology and is being ambitious in looking for a foothold in first-line non-small cell lung cancer (NSCLC) for its PD-1 immunotherapy Jemperli (dostarlimab).

But while the company has just announced a minor trial success in a head-to-head study with Merck & Co’s...